GlassScriptPhysician profile
Robin Miller
NPI 1316906159
$4,310.67
in general payments reported to CMS, 2019-2025
18 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,212 · 2022: $594 · 2023: $1,582 · 2024: $304 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,151.92 | 2021-2025 | Xifaxan |
| Abbvie INC. | $650.42 | 2021-2025 | |
| Janssen Biotech, INC. | $232.62 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $180.10 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $165.86 | 2021-2022 | |
| Organogenesis INC. | $156.35 | 2022-2023 | Puraply |
| Gilead Sciences, INC. | $131.35 | 2021-2023 | |
| Evoke Pharma, INC. | $124.28 | 2021 | |
| Celltrion USA INC. | $122.98 | 2025 | Zymfentra |
| Boston Scientific Corporation | $107.52 | 2023 | Ranger |
| Lilly USA, LLC | $98.82 | 2024 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $48.99 | 2024-2025 | Dupixent |
| Daiichi Sankyo INC. | $39.89 | 2022 | |
| Organon LLC | $26.51 | 2024 | |
| Ferring Pharmaceuticals INC. | $26.42 | 2025 | Rebyota |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $17.86 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $15.40 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.